REVLIMID® (lenalidomide) logo

This site is intended for US audiences only.

This site is intended for US audiences only.

REVLIMID is a prescription medicine used to treat people with mantle cell lymphoma (MCL) when the disease comes back or becomes worse after treatment with two prior medicines, one of which included bortezomib. MCL is a cancer of a type of white blood cell called lymphocytes that are in the lymph nodes.
REVLIMID should not be used to treat people who have chronic lymphocytic leukemia (CLL) unless they are participants in a controlled clinical trial. It is not known if REVLIMID is safe and effective in children.

HEALTHCARE TEAM

Review important information about working with your healthcare team

LEARN MORE

CAREGIVER SUPPORT

Find information and support that
may be helpful to caregivers

LEARN MORE
Hypothetical doctor, a REVLIMID® (lenalidomide) patient with MCL (mantle cell lymphoma), and their loved one smiling

ORGANIZATIONS

Explore organizations that provide support around mantle cell lymphoma

VIEW ORGANIZATIONS
REVLIMID® (lenalidomide) patient brochure and treatment tracker REVLIMID® (lenalidomide) patient brochure and treatment tracker

Patient Brochure & Treatment Tracker

A guide for patients with relapsed or refractory mantle cell lymphoma.

DOWNLOAD
MCL (mantle cell lymphoma) glossary MCL (mantle cell lymphoma) glossary

Glossary

Learn terms to help you better understand mantle cell lymphoma.

LEARN MORE